English

• 24 Mar, 2026
  Spago Nanomedical’s abstract on Tumorad® accepted for presentation at radiopharma conference
• 17 Mar, 2026
  Spago Nanomedical continues recruitment in the phase I/IIa Tumorad-01 study following positive DMC recommendation
• 10 Mar, 2026
  Spago Nanomedical strengthens CMC and supply capabilities to support next phase of Tumorad development
• 5 Feb, 2026
  Spago Nanomedical year-end report January-December, 2025
• 8 Dec, 2025
  Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2026
• 24 Nov, 2025
  Spago Nanomedical announces outcome of oversubscribed rights issue
• 7 Nov, 2025
  The subscription period in Spago Nanomedical’s rights issue begins today
• 6 Nov, 2025
  Spago Nanomedical publishes information document in connection with forthcoming rights issue
• 29 Oct, 2025
  Spago Nanomedical resolves on a rights issue of approximately SEK 25 million to advance Tumorad
• 29 Oct, 2025
  Spago Nanomedical interim report January-September 2025